College
Rowan-Virtua School of Osteopathic Medicine
Keywords
CAR T-cell therapy, Tisagenlecleucel therapy, Standard of Care, acute lymphoblastic leukemia, treatment outcomes, socioeconomic factors, cost-effectiveness, quality-adjusted life years, child, pediatric
Date of Presentation
5-2-2024 12:00 AM
Poster Abstract
Aims
This review aims to assess the correlations between outcomes and cost of treatment methods for pediatric acute lymphoblastic leukemia patients, specifically comparing CAR T-cell therapy and Standard-of-Care (SoC) therapy. The socioeconomic background of patients will also be taken into consideration to see if there are differences in their outcomes.
Methods
Peer-reviewed publications were collected from PubMed and Web of Science. The keyword strings used were “acute lymphoblastic leukemia,” “pediatric acute lymphoblastic leukemia,” “pediatric,” “CAR T-cell therapy,” and “cost-effectiveness.” 27 citations were obtained. Titles were screened by 6 authors. Articles met the inclusion criteria including potential Quality-Adjusted Life Year (QALY) gains, mean price of CAR T-cell therapy and SoC therapy. The outcomes measured were presented in terms of total treatment cost for both CAR T-cell therapy and SoC treatments such as chemotherapy and/or hematopoietic stem-cell transplant.
Results
In the 6 comparative studies used, the overall cost and QALY of CAR T-cell therapy was higher than the SoC. In 4 of 6 studies, the price per QALY for CAR T-cell therapy was lower than the SoC treatment, ranging from $24,696 - $304,611 less per QALY. In the other 2 studies, the price per QALY for CAR T-cell therapy was higher by $6,452 and $18,874 per QALY.
Conclusions
Overall, CAR T-cell therapy was more expensive; however, it provided more QALY than other SoC’s. Future studies could determine if and how socioeconomic status, region, and race impact QALY for CAR T-cell, and how to mitigate barriers to access.
Disciplines
Health and Medical Administration | Hemic and Lymphatic Diseases | Inequality and Stratification | Medicine and Health | Medicine and Health Sciences | Oncology | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Pediatrics | Therapeutics
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.171_2024
Included in
Health and Medical Administration Commons, Hemic and Lymphatic Diseases Commons, Inequality and Stratification Commons, Medicine and Health Commons, Oncology Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Pediatrics Commons, Therapeutics Commons
Cost-Effectiveness and Outcomes of Utilizing Tisagenlecleucel Therapy (CAR T-cell) in Pediatric Acute Lymphoblastic Leukemia in Comparison to Standard of Care (SoC) Therapies: A Scoping Review
Aims
This review aims to assess the correlations between outcomes and cost of treatment methods for pediatric acute lymphoblastic leukemia patients, specifically comparing CAR T-cell therapy and Standard-of-Care (SoC) therapy. The socioeconomic background of patients will also be taken into consideration to see if there are differences in their outcomes.
Methods
Peer-reviewed publications were collected from PubMed and Web of Science. The keyword strings used were “acute lymphoblastic leukemia,” “pediatric acute lymphoblastic leukemia,” “pediatric,” “CAR T-cell therapy,” and “cost-effectiveness.” 27 citations were obtained. Titles were screened by 6 authors. Articles met the inclusion criteria including potential Quality-Adjusted Life Year (QALY) gains, mean price of CAR T-cell therapy and SoC therapy. The outcomes measured were presented in terms of total treatment cost for both CAR T-cell therapy and SoC treatments such as chemotherapy and/or hematopoietic stem-cell transplant.
Results
In the 6 comparative studies used, the overall cost and QALY of CAR T-cell therapy was higher than the SoC. In 4 of 6 studies, the price per QALY for CAR T-cell therapy was lower than the SoC treatment, ranging from $24,696 - $304,611 less per QALY. In the other 2 studies, the price per QALY for CAR T-cell therapy was higher by $6,452 and $18,874 per QALY.
Conclusions
Overall, CAR T-cell therapy was more expensive; however, it provided more QALY than other SoC’s. Future studies could determine if and how socioeconomic status, region, and race impact QALY for CAR T-cell, and how to mitigate barriers to access.